Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 4 Next >
Natera Provides Update on Patent Litigation with NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
From Natera, Inc.
Via Business Wire
Tickers NTRA
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Second Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report Its Second Quarter Results on August 7, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
Tickers NTRA
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
Tickers NTRA
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
Tickers NTRA
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.